Clinical manifestations and efficacy of olaparib (Olaparib, Lipadro) combined with temozolomide

The combination treatment of olaparib and temozolomide has demonstrated significant clinical performance and good efficacy in small cell lung cancer (SCLC).

In the relevant clinical trials, the subjects were patients with small cell lung cancer. Their average age was 63 years old, with a wide age range. These patients had received at least one previous treatment and relapsed, and some of them also had brain metastases. Such subject characteristics make the research results more practical.

In clinical trials, the medication regimens of olaparib and temozolomide were carefully designed. Olaparib is administered orally twice a day, while temozolomide is administered every 21 days in a treatment cycle and is used on a specific number of days in a treatment cycle. This medication regimen ensures the effectiveness of the medication while also reducing the patient's medication burden as much as possible.

According to clinical trial data, the objective response rate of olaparib combined with temozolomide reached 41.7%. This means that nearly half of the patients who received the treatment saw their tumors shrink or disappear. This data is undoubtedly exciting for small cell lung cancer, a highly aggressive malignant tumor.

In addition to the objective response rate, the disease control rate of this combination therapy also reached 79.2%. This suggests that tumor growth and spread are effectively controlled in the majority of patients treated.

Among patients who received olaparib in combination with temozolomide, the median progression-free survival was 4.2 months and the median overall survival was 8.5 months. These data indicate that this combination therapy can significantly extend the survival time of patients with small cell lung cancer.